Status:

RECRUITING

Efficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction.

Lead Sponsor:

Loma Linda University

Conditions:

Dental Pain and Sensation Disorder

Pain, Postoperative

Eligibility:

All Genders

18-59 years

Phase:

PHASE4

Brief Summary

This study is a double-blind, randomized, prospective, placebo-controlled single-center clinical research study in which 600 mg of gabapentin or placebo will be administered 2 hours preoperatively to ...

Detailed Description

Since the 1990s, the amount of prescribed opioids has begun growing. According to the Center for Disease Control, more than 130 people die every day due to opioid overdose. Many medical and surgical s...

Eligibility Criteria

Inclusion

  • Subjects must be at or older than 18.
  • Screened body mass index (BMI) between 18-35 kg/m2.
  • American Society of Anesthesiologists Classification I and II.
  • Subjects must be willing and able to comply with protocol requirements.
  • Subjects must be able to understand the informed consent and must be able to sign a written informed consent form prior to the initiation of any study procedures.
  • A subject must have at least 1 partial or fully impacted third molar tooth removal.

Exclusion

  • hypersensitivity to gabapentinoids;
  • history of chronic opioid or gabapentin usage (regular use of opioids \>3 months)
  • history of recreational drug usage
  • a history or clinical manifestations of significant metabolic, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, hepatic, renal, urologic, musculoskeletal, psychiatric, or immunologic disorder, any acute, clinically significant illness or condition within 14 days prior to Day 1.
  • Patients with baseline pain.
  • Patients with any oral pathology will be excluded.
  • Pregnant or breastfeeding patients
  • An individual not legally competent to consent (e.g., incapacitated individuals, incompetents, minors)

Key Trial Info

Start Date :

June 16 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 1 2026

Estimated Enrollment :

98 Patients enrolled

Trial Details

Trial ID

NCT04860141

Start Date

June 16 2021

End Date

January 1 2026

Last Update

April 6 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Loma Linda University Health

Loma Linda, California, United States, 92354